A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension
Autor: | Paulette A. Lyle, Peter U. Feig, Gilbert W. Gleim, Joseph Rubino, Hongyan Zhang, Beth Soffer, Shahnaz Shahinfar, Thomas W. Littlejohn |
---|---|
Rok vydání: | 2006 |
Předmět: |
Adult
Male medicine.medical_specialty Randomization Pharmacology Essential hypertension Losartan law.invention Hydrochlorothiazide Double-Blind Method Randomized controlled trial law Internal medicine Humans Medicine Pharmacology (medical) Antihypertensive Agents Aged business.industry Middle Aged medicine.disease Angiotensin II Treatment Outcome Blood pressure Tolerability Drug Therapy Combination Female business medicine.drug |
Zdroj: | Clinical Therapeutics. 28:1639-1648 |
ISSN: | 0149-2918 |
DOI: | 10.1016/j.clinthera.2006.10.014 |
Popis: | Because patients with hypertension may require1 antihypertensive agent to control blood pressure (BP), physicians often prescribe a fixed combination of antihypertensive medications.This study evaluated the effect of adding low-dose hydrochlorothiazide 12.5 mg (HCTZ12.5) to high-dose losartan 100 mg (L100) in patients with hypertension whose BP was inadequately controlled with L100 monotherapy.Enrolled in this multicenter, randomized, double-blind, parallel-group, filter study were patients agedor =18 years with a mean trough sitting diastolic BP (SiDBP) of 95 to 120 mm Hg. Patients were treated with L100 QD for 4 weeks. Patients who did not achieve adequate BP control were randomly assigned to receive L100/HCTZ12.5 or L100 QD for 6 weeks. The primary efficacy measure was the mean change in trough SiDBP from baseline in the 2 groups. Responders were defined as patients with a mean trough SiDBP of90 mm Hg or patients who had aor =10-mm Hg decrease in mean trough SiDBP.Demographic characteristics were similar between treatment groups. The patients randomized to the double-blind treatment period were mostly white (65.1%) and male (57.5%), with a mean age of 53.8 years. The mean (SD) duration of hypertension at baseline was 9.7 (8.5) years. The proportion of patients previously treated with antihypertensive therapy was 76.7%. Of the 367 patients enrolled in the L100 filter period, 292 patients had BP inadequately controlled with L100 monotherapy and were randomized to receive L100 (n = 145) or L100/HCTZ12.5 (n = 147). At week 6 after randomization, mean trough SiDBP was significantly lower in the L100/HCTZ12.5 group than in the L100 group (-8.3 vs -5.2, respectively; P0.001). The between-group difference was -3.0 mm Hg (95 % CI, -4.6 to -1.40; P0.001), and the proportion of responders was significantly greater in the L100/HCTZ12.5 group than in the L100 group (63.0% vs 44.4%; P0.001). The incidence of adverse events (AEs) occurring in2% of patients during the double-blind period was similar for both groups. AEs occurring in the L100 group and the L100/HCTZ12.5 group included respiratory tract infection (6.2% vs 3.4%, respectively), dizziness (2.1% vs 0.7%), and headache (0.7% vs 3.4%).After 6 weeks of therapy, L100/HCTZ12.5 was associated with greater antihypertensive efficacy than L100, as measured by the change in mean trough SiDBP The percentage of responders was significantly greater in the L100/HCTZ12.5 group than in the L100 group. |
Databáze: | OpenAIRE |
Externí odkaz: |